468-01-004 ISMRM Abstract

Quantitative MRI assessment of cerebellar neurodegeneration and metabolic alterations in Lafora disease

Primary: Neuro - Epilepsy

Secondary: Contrast Mechanisms - Spectroscopy

468-01-004 · Quantitative Neuroimaging of Neurodegeneration, Metabolism, and Brain Microstructure · Tuesday, 12 May, 8:20 AM–9:15 AM · Digital Posters Row I

Keywords: In vivo proton magnetic resonance spectroscopy Quantitative Susceptibility Mapping (QSM) Neurodegeneration Biomarker Volumetric Analysis Lafora disease

Accepted

Lorenzo Motta ¹, Greta Venturi¹, Francesca Punzetti¹, Lorenzo Muccioli^2,3, Raffaele Lodi^1,2, Francesca Bisulli^2,3, Caterina Tonon^1,2

¹Programma Neuroimmagini Funzionali e Molecolari, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

²Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy

³IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

Presenting Author: Lorenzo Motta

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Pondrelli F, Muccioli L, Licchetta L, et al. Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis. Orphanet J Rare Dis. 2021;16(1):362. Published 2021 Aug 16. doi:10.1186/s13023-021-01989-w [doi]

2. Sullivan MA, Nitschke S, Steup M, Minassian BA, Nitschke F. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan. Int J Mol Sci. 2017;18(8):1743. Published 2017 Aug 11. doi:10.3390/ijms18081743 [doi]

3. Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14(10):606-617. doi:10.1038/s41582-018-0057-0 [doi]

4. Ganesh S, Delgado-Escueta AV, Sakamoto T, et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002;11(11):1251-1262. doi:10.1093/hmg/11.11.1251 [doi]

5. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, Roach PJ. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin. J Biol Chem. 2010;285(33):25372-25381. doi:10.1074/jbc.M110.148668 [doi]

6. Villanueva V, Alvarez-Linera J, Gómez-Garre P, Gutiérrez J, Serratosa JM. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia. 2006 Apr;47(4):788-92. doi: 10.1111/j.1528-1167.2006.00526.x. PMID: 16650146. [doi] [pmid]

7. Altindag E, Kara B, Baykan B, Terzibasioglu E, Sencer S, Onat L, Sirvanci M. MR spectroscopy findings in Lafora disease. J Neuroimaging. 2009 Oct;19(4):359-65. doi: 10.1111/j.1552-6569.2008.00325.x. Epub 2008 Nov 14. PMID: 19040628. [doi] [pmid]

8. Diedrichsen J. A spatially unbiased atlas template of the human cerebellum. Neuroimage. 2006 Oct 15;33(1):127-38. doi: 10.1016/j.neuroimage.2006.05.056. Epub 2006 Aug 14. PMID: 16904911. [doi] [pmid]

9. QSM Consensus Organization Committee; Bilgic B, Costagli M, Chan KS, Duyn J, Langkammer C, Lee J, Li X, Liu C, Marques JP, Milovic C, Robinson SD, Schweser F, Shmueli K, Spincemaille P, Straub S, van Zijl P, Wang Y; ISMRM Electro-Magnetic Tissue Properties Study Group. Recommended implementation of quantitative susceptibility mapping for clinical research in the brain: A consensus of the ISMRM electro-magnetic tissue properties study group. Magn Reson Med. 2024 May;91(5):1834-1862. doi: 10.1002/mrm.30006. Epub 2024 Jan 21. PMID: 38247051; PMCID: PMC10950544 [doi] [pmid]

10. Öz, G., Deelchand, D. K., Wijnen, J. P., Mlynárik, V., Xin, L., Mekle, R., … the Experts’ Working Group on Advanced Single Voxel H MRS. (2021). Advanced single voxel1 H magnetic resonance spectroscopy techniques in humans: Experts’ consensus recommendations. NMR in Biomedicine, 34(5), e4236. doi: 10.1002/nbm.4236 [doi]

11. Ravanfar P, Loi SM, Syeda WT, Van Rheenen TE, Bush AI, Desmond P, Cropley VL, Lane DJR, Opazo CM, Moffat BA, Velakoulis D, Pantelis C. Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases. Front Neurosci. 2021 Feb 18;15:618435. doi: 10.3389/fnins.2021.618435. PMID: 33679303; PMCID: PMC7930077. [doi] [pmid]

12. Nikparast, F., Ganji, Z., Danesh Doust, M. et al. Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?. Insights Imaging 13, 74 (2022). https://doi.org/10.1186/s13244-022-01207-6 [doi]

13. Chan KL, Panatpur A, Messahel S, Dahshi H, Johnson T, Henning A, Ren J, Minassian BA. 1H and 31P magnetic resonance spectroscopy reveals potential pathogenic and biomarker metabolite alterations in Lafora disease. Brain Commun. 2024 Mar 26;6(2):fcae104. doi: 10.1093/braincomms/fcae104. PMID: 38585668; PMCID: PMC10998360. [doi] [pmid]

14. Pichiecchio A, Veggiotti P, Cardinali S, Longaretti F, Poloni GU, Uggetti C. Lafora disease: spectroscopy study correlated with neuropsychological findings. Eur J Paediatr Neurol. 2008 Jul;12(4):342-7. doi: 10.1016/j.ejpn.2007.09.008. Epub 2007 Dec 11. PMID: 18063398. [doi] [pmid]

15. Koppelmans, V., Hoogendam, Y. Y., Hirsiger, S., Mérillat, S., Jäncke, L., & Seidler, R. D. (2017). Regional cerebellar volumetric correlates of manual motor and cognitive function. Brain Structure and Function, 222(4), 1929–1944. doi: 10.1007/s00429-016-1317-7 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/468-01-004